This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

ASCO, Chicago, IL, USA, 1-5 June 2018

Phase I study of afatinib and radiotherapy with or without temozolomide in newly diagnosed glioblastoma

Frank Saran, Liam Welsh, Allan James, Catherine McBain, Sarah Jefferies, Fiona Harris, Agnieszka Cseh, Karine Pemberton, Jennifer Schaible, Shaun Bender, Michael Brada

Saran et al ASCO 2018 poster

Related Material

Learn more about the science behind this poster in the videos, papers and other materials below.

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

Reardon DA, et al. Neuro Oncol. 2015 Mar; 17(3): 430–439

FOR HEALTHCARE PROFESSIONALS ONLY.

 

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

Related information

ASCO 2018

Find information on Boehringer Ingelheim's clinical data and activities at ASCO 2018

 

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib
Back to top